Dynavax Technologies Corporation (DVAX): $1.65 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.04. The value of trades done on upticks was $46.61 million, whereas, trades done on downticks were valued at $44.97 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $2.7 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $0.55 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 4.87 was strongly in favor of the bulls. The money flow in block trades was $2.14 million. Dynavax Technologies Corporation (DVAX) fell $5.03 traded at $10.91, a change of -31.56% over the previous day. The stock is -32.94% for the week.
The company Insiders own 2% of Dynavax Technologies Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 31.59% . Institutional Investors own 83.9% of Dynavax Technologies Corporation shares. During last six month period, the net percent change held by insiders has seen a change of 110%.
In a related news, Janssen Robert, Officer (Vice President) of DYNAVAX TECHNOLOGIES CORP had purchased 1,452 shares on June 28, 2016 in a transaction. The price per share was $13.68 and the total amount of the disclosed transaction was $19,863.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Dynavax Technologies Corporation (NASDAQ:DVAX): stock was range-bound between the intraday low of $10.14 and the intraday high of $16.19 after having opened at $16.01 on Fridays session. The stock finally closed in the red at $16.01, a loss of -31.56%. The stock remained in the red for the whole trading day. The total traded volume was 15,822,144 shares. The stock failed to cross $16.19 in Fridays trading. The stocks closing price on Thursday was $15.94.
Dynavax Technologies Corporation (DVAX) : During the past 4 weeks, traders have been relatively bearish on Dynavax Technologies Corporation (DVAX), hence the stock is down -34.7% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -33.28% relative to the S&P 500. The 4-week change in the price of the stock is -34.79% and the stock has fallen -32.94% in the past 1 week.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.